Monoclonal antibody 35B5 as well as preparation method and application thereof

Through the development of monoclonal antibody 35B5, the problem of poor neutralization effect against the RBD domain of the new coronavirus spike protein in the existing technology has been solved, and effective inhibition of multiple new coronavirus strains, including original strains and mutant strains, has been achieved , significantly reducing virus titers and inflammatory responses.

CN113388031AActive Publication Date: 2021-09-14SHANGHAI INST FOR ADVANCED STUDY OF ZHEJIANG UNIV
5 Cites 8 Cited by

Patent Information

Application Number
CN202110940804.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2021-08-17
Publication Date
2021-09-14
Estimated Expiration
2041-08-17

AI Technical Summary

Technical Problem

There is a lack of effective antibodies against the RBD domain of the spike protein of the new coronavirus in the existing technology. Especially when faced with multiple mutant strains, the neutralizing effect is poor, and deficiencies in preparation and application lead to limited therapeutic effects.

Method used

A monoclonal antibody 35B5 and its antigen-binding fragment were developed. By specifically binding to specific amino acid residues of the spike protein, blocking its binding to the ACE2 receptor, it has high affinity and can effectively neutralize a variety of new coronavirus strains. , including original strains and mutant strains.

Benefits of technology

Antibody 35B5 significantly reduces the viral titer of SARS-CoV-2, reduces the expression of inflammatory factors, and improves inflammatory infiltration. Its binding structure with RBD avoids mutation sites, ensuring effective inhibition of multiple mutant strains.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a monoclonal antibody 35B5 as well as a preparation method and application thereof. According to the monoclonal antibody 35B5, the neutralizing antibody 35B5 aiming at the RBD structural domain of the novel coronavirus is prepared, the antibody 35B5 can be effectively combined with the RBD structural domain of the S protein of the novel coronavirus through surface plasmon resonance detection in vitro, and the neutralizing capability of the antibody 35B5 is verified through a transgenic mouse infection model; the inhibition effect of the neutralizing antibody 35B5 on the lung virus titer and related inflammatory factors after novel coronavirus infection is determined, and the result shows that the neutralizing antibody can obviously inhibit virus replication in vivo and reduce inflammatory factor generation and lung inflammation infiltration; and the monoclonal neutralizing antibody 35B5 inhibits the novel coronavirus from entering host cells, achieves the therapeutic effect of the novel coronavirus neutralizing antibody, and can be effectively used for treating or preventing respiratory system injury caused by novel coronavirus infection.
Need to check novelty before this filing date? Find Prior Art